Draegerwerk AG & Co. KGaA · XETR:DRW8

Draegerwerk AG & Co. KGaA — Drägerwerk AG & Co. KGaA — Merger or Acquisition (May 2002)

13 slides from Draegerwerk AG & Co. KGaA's merger presentation, May 30, 2002

  1. Slide 1: Nothing is more constant than change.

    SUBJECT TO APPROVAL Nothing is more constant than change. May 30, 2002 1

  2. Slide 2: Consolidation is a result of increasing pressure on health care providers

    Consolidation is a result of increasing pressure on health care providers who in turn must change their SUBJECT TO APPROVAL processes and structures. ed cost increas ition coverag e compet reg nt ion demulator tie and y pa sfact s i sat Process and Structural Changes 2

  3. Slide 3: Hospitals will have a stronger influence through supplier selection

    Hospitals will have a stronger influence on shaping SUBJECT TO the future of our market through supplier selection. APPROVAL The WINNING Suppliers Ÿ Orient products and services toward the patient care process Ÿ Bundle products and services to offer customers complete solutions Ÿ Facilitate effectiv

  4. Slide 4: Dräger Medical is taking a proactive role to remain a winning supplier

    SUBJECT TO APPROVAL Dräger Medical is taking a proactive role to remain a winning supplier in our market with: • a more complete portfolio • a more solid sales and service network • more wide-ranging technological expertise • a higher level of clinical process integration 4

  5. Slide 5: The Siemens EM Division will be integrated into Dräger Medical worldwide

    The Siemens EM Division will be integrated SUBJECT TO into the Dräger Medical organization worldwide*. APPROVAL Siemens AG Drägerwerk AG Siemens Medical Solutions ... Joint Venture ... EM MR CT US HS ... *conceptual display of the respective world businesses 5

  6. Slide 6: Drägerwerk AG will hold a majority share of 65%

    Drägerwerk AG will hold a majority share SUBJECT TO of 65% and Siemens AG a minority of 35%. APPROVAL Drägerwerk AG Siemens AG 65% 35% Dräger Medical AG & Co. KGaA Dräger Med Dräger Med Dräger Med Dräger Med ... Inc. S.A. Ltd. N.V. • Siemens AG will hold 35% of the private shares (Kommanditaktien).

  7. Slide 7: The logo will change giving the JV a more independent identity

    The logo will change giving the JV a more SUBJECT TO independent identity. APPROVAL • The JV will carry a new logo with “A Dräger and Siemens Company” added: • The legal form of the JV will be Dräger Medical AG & Co. KGaA and will be the mother company of the Dräger Medical JV subsidiaries. • The JV

  8. Slide 8: All local Siemens EM and Dräger Medical organizations will be integrated

    All local Siemens EM and Dräger Medical organizations SUBJECT TO will be integrated. APPROVAL Dräger Medical contributes its entire organization including: • All products and services worldwide • All R&D, manufacturing, sales, marketing and service, including distributor contracts • All Dräger Medic

  9. Slide 9: The joint venture will have total sales exceeding €1.2 billion

    The joint venture will have a total sales volume SUBJECT TO exceeding €1.2 billion and will employ 6,400 people. APPROVAL Stockholm Glasgow Best Lübeck Danvers Shanghai Telford Dräger Medical after JV 1400 Worldwide Organization Sales Volume 1200 Dräger Medical • 6,400 employees (ca. 4,800 Dräger, 1

  10. Slide 10: Dräger Medical and Siemens Med agreed to cooperate in R&D of IT and sales

    In addition, Dräger Medical and Siemens Med agreed SUBJECT TO to cooperate closely in the R&D of IT and in sales. APPROVAL Both companies additionally agreed to cooperate in: - Technology development to enable the seamless integration of point-of-care data into departmental on to hospital-wide IT ne

  11. Slide 11: Customers will benefit from the combined expertise

    Customers will benefit from the combined SUBJECT TO expertise the JV has to offer. APPROVAL • Support of workflow solutions and clinical decision-making for more effective and cost-efficient patient care. • A more complete portfolio in acute point-of-care solutions and a stronger presence around the

  12. Slide 12: The JV must still be approved by the respective authorities

    The JV must still be approved by the respective SUBJECT TO authorities. APPROVAL • A “memorandum of understanding” or MOU (agreement to join hands) was announced by both parties on May 30, 2002. • The respective authorities will review the planned JV. We expect their final decision within 6 months a

  13. Slide 13: Summary: reasons for Dräger Medical to enter the joint venture

    Summary: The most important reasons for SUBJECT TO Dräger Medical to enter the joint venture: APPROVAL • To add competence in monitoring by integrating Siemens’ expertise in this field and thereby be able to develop and offer more complete and integrated solutions at the acute point-of-care. • To ta

Drägerwerk AG & Co. KGaA — Merger or Acquisition (May 2002) on 6ix